<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00071890</url>
  </required_header>
  <id_info>
    <org_study_id>040018</org_study_id>
    <secondary_id>04-I-0018</secondary_id>
    <secondary_id>ANRS 118 ILIADE</secondary_id>
    <nct_id>NCT00071890</nct_id>
  </id_info>
  <brief_title>Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx</brief_title>
  <acronym>ILIADE</acronym>
  <official_title>Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Anti-Retroviral TX in HIV Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm(3) Who Have Received Anti-Retroviral TX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether interleukin-2 (IL-2) given before the interruption of&#xD;
      antiretroviral (ARV) treatment could significantly extend the period of time that a patient&#xD;
      is temporarily not taking ARV treatment and also preserve CD4 counts above 350 cells per&#xD;
      microliter. There will be an evaluation of the toxicity, or extremely harmful effects, of&#xD;
      ARV, and the effect on quality of life.&#xD;
&#xD;
      The use of ARV medications has greatly improved the condition and mortality of HIV-infected&#xD;
      patients. But when used long term, those medications have been associated with great&#xD;
      toxicities and medication fatigue. As a result, patients may not adhere to ARV use, and&#xD;
      resistance to viruses may grow. The CD4 molecule is on the surface of helper T-lymphocytes,&#xD;
      or T-helper cells. It serves as the primary receptor for HIV-1 and HIV-2, allowing the virus&#xD;
      to gain entry into its host. The CD4 count increases immediately in response to ARV, giving&#xD;
      an estimate of the state of a patient's immune system. Thus, it is a strong marker of the&#xD;
      immediate risk of an opportunistic infection, one that takes advantage of a person's weakened&#xD;
      immune system. IL-2 is a molecule naturally produced by activated T cells. In patients with&#xD;
      HIV, IL-2 treatment can increase CD4 counts but the clinical importance of this increase is&#xD;
      not clear. This study will compare the decline in CD4 count, when ARV is interrupted, in two&#xD;
      random groups of participants: (1) those who will receive three cycles of IL-2 (one every 8&#xD;
      weeks) in combination with ARV therapy for the first 24 weeks of the study before stopping&#xD;
      ARV and (2) those who will receive ARV therapy without IL-2 for 24 weeks before stopping ARV.&#xD;
&#xD;
      Patients 18 years of age or older who have HIV-1 infection and who have been on ARV therapy&#xD;
      for at least 1 year, and who currently have a CD4 count 500 cells per microliter or higher&#xD;
      and never had a CD4 count of less than 200 cells per microliter and a viral load less than&#xD;
      the limit of detection, may be eligible for this study.&#xD;
&#xD;
      Participants will undergo the following procedures and tests:&#xD;
&#xD;
        -  Physical examination.&#xD;
&#xD;
        -  Blood tests to measure blood lipids (fats), sugar, complete blood count including&#xD;
           platelets, and chemistries.&#xD;
&#xD;
        -  Assessment of fat distribution.&#xD;
&#xD;
        -  Questionnaire about quality of life.&#xD;
&#xD;
      In addition, those participants who are randomly placed in the group receiving IL-2 and ARV&#xD;
      will get an echocardiogram at the beginning of the study and at week 24. They will receive a&#xD;
      starting dose of 6 million units of IL-2 as an injection under the skin twice a day. Each of&#xD;
      the three IL-2 cycles will last 5 days. After the 24-week period, participants in both groups&#xD;
      will stop taking ARV medications if their CD4 count is still equal to or greater than 500&#xD;
      cells per microliter. The study will continue into 120 weeks. Participants will be asked to&#xD;
      continue to visit the clinic every 8 weeks for evaluation of their viral load and CD4 counts.&#xD;
      Every 24 weeks, they will be asked to answer a questionnaire about their quality of life.&#xD;
      Blood tests and other measurements will also be done as follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of antiretroviral (ARV) medications has greatly improved morbidity and mortality of&#xD;
      HIV-infected patients but long-term use of these agents has been associated with significant&#xD;
      toxicities and medication fatigue that can lead to problems with adherence and eventual&#xD;
      development of virologic resistance. The spectrum of ARV toxicities is broad including the&#xD;
      development of lipodystrophy syndrome with lipid abnormalities and glucose intolerance or&#xD;
      diabetes, while increasing evidence suggests an increased risk of cardiovascular&#xD;
      complications in ARV-treated HIV-infected individuals. Current PHHS treatment guidelines&#xD;
      recommend deferring ARV treatment initiation in asymptomatic HIV-infected individuals with&#xD;
      CD4 count greater than or equal to 350 cells/micro liter, and treatment initiation after the&#xD;
      CD4 count is less than 350 cells/micro liter. Several patients who started antiretroviral&#xD;
      therapy at higher CD4 counts (based on older treatment initiation guidelines) or have&#xD;
      experienced significant immunologic reconstitution after ARV initiation, elect to interrupt&#xD;
      antiretroviral therapy until their CD4 count reaches the level of current recommendations for&#xD;
      therapy initiation (less than 350 cells/micro liter).&#xD;
&#xD;
      Studies to date suggest that baseline and nadir CD4 count are the best predictors of a longer&#xD;
      duration of treatment interruption that may be more beneficial with respect to reversal or&#xD;
      delay of long-term ARV-associated toxicity and improved quality of life. It is known that&#xD;
      intermittent cycles of IL-2 administration can lead to expansion of the CD4 pool and prolong&#xD;
      survival of CD4 T cells. In this study the hypothesis tested is that IL-2 given prior to ARV&#xD;
      treatment interruption could significantly prolong the period of ARV treatment interruption&#xD;
      with preservation of CD4 counts above 350 cells/micro liter, and that this prolongation will&#xD;
      be beneficial with respect to antiretroviral related toxicity and quality of life.&#xD;
&#xD;
      The study will have two parts: during the first part (24 weeks) patients will be randomized&#xD;
      1:1 to either receive three cycles or IL-2 with their ARV therapy or ARV therapy alone. In&#xD;
      the second part (week 24 to week 120), all participants will interrupt therapy and restart&#xD;
      when CD4 is less than 350 cells/micro liter. The main comparison will be at week 72, when the&#xD;
      proportion of patients from the two groups who remain off drugs and have a CD4 greater than&#xD;
      350 cells/micro liter will be compared. At regular intervals (every 24 weeks) lipodystrophy&#xD;
      measurements and quality of life questionnaires will be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Without Failure of Strategy From Week 0 to Week 72</measure>
    <time_frame>week 72</time_frame>
    <description>A failure of strategy is defined on the first occurrence of one of the following events:&#xD;
CD4 T-lymphocyte count becomes &lt; 350 cells/mm3 between Wk0 and Wk72 (count confirmed by a 2nd measurement after 2-4 weeks&#xD;
Planned interruption of therapy at Wk24 cannot be done for any reason;&#xD;
Anti-retroviral treatment is restarted between Wk24 and Wk72 for any reason&#xD;
Subject experiences clinical progression of HIV infection to a stage C AIDS diagnosis (appendix I)&#xD;
Subject expires between Wk0 and Wk72 (whatever the cause of death)&#xD;
Subject is lost to follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4 Counts at Week 72</measure>
    <time_frame>week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AIDS Events</measure>
    <time_frame>Overall study</time_frame>
    <description>AIDS defined events according to CDC classification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Interleukin 2 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HAART (standard of care) and three cycles of IL-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HAART alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin 2</intervention_name>
    <description>Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)</description>
    <arm_group_label>Interleukin 2 group</arm_group_label>
    <other_name>Interleukin-2</other_name>
    <other_name>IL-2</other_name>
    <other_name>aldesleukin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAART</intervention_name>
    <description>HAART from week 0 to week 24</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Interleukin 2 group</arm_group_label>
    <other_name>Antiretroviral treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment interruption</intervention_name>
    <description>HAART is interrupted from week 24 in both arms</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Interleukin 2 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Age greater than or equal to 18 years.&#xD;
&#xD;
        HIV-1 infection confirmed by ELISA and Western Blot before screening.&#xD;
&#xD;
        Category A or B HIV-1 infection.&#xD;
&#xD;
        Antiretroviral treatment:&#xD;
&#xD;
          -  started at least 12 months prior to screening visit;&#xD;
&#xD;
          -  stable and continuous for at least 12 weeks prior to screening visit;&#xD;
&#xD;
          -  modified no more than once for virologic failure.&#xD;
&#xD;
        IL-2 naive&#xD;
&#xD;
        CD-4(+) T-lymphocyte count greater than or equal to 500 cells/mm(3) in the twelve weeks&#xD;
        prior to screening (historical) and at screening.&#xD;
&#xD;
        Nadir CD4(+) T-lymphocyte count greater than or equal to 200 cells/mm(3) prior to screening&#xD;
        visit (that is, no measurement whose values may be less than 200/mm(3) since diagnosis of&#xD;
        the HIV infection.&#xD;
&#xD;
        Plasma HIV RNA less than 50 copies/ml in the 12 weeks preceding screening (historical, less&#xD;
        than limit of detection if different method and/or cut off used) and at screening.&#xD;
&#xD;
        For women of child-bearing age: use of effective contraception (hormonal such as birth&#xD;
        control pill or injections, intrauterine device, surgical sterilization and/or mechanical&#xD;
        barrier methods such as diaphragm or condoms); for all participants agreement to fully&#xD;
        comply with prevention of transmission recommendations during periods of viremia if&#xD;
        sexually active (latex condoms with or without additional barrier methods).&#xD;
&#xD;
        Desire to interrupt antiretroviral therapy.&#xD;
&#xD;
        Ability to sign informed consent (no later than W-2).&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Previous treatment with IL-2.&#xD;
&#xD;
        Combined treatment with interferon, other interleukins, anti-HIV vaccines, systemic (not&#xD;
        topical or inhaled) corticosteroids and hydroxyurea within the previous 12 weeks.&#xD;
&#xD;
        Diagnosis of AIDS.&#xD;
&#xD;
        Acute infection in the 14 days preceding inclusion.&#xD;
&#xD;
        Pregnant, lactating woman desiring conception or not using contraception.&#xD;
&#xD;
        Hemoglobin less than 10 g/dl; neutrophils less than 1,000/mm(3); platelets less than&#xD;
        50,000/mm(3); creatinine greater than 1.5 times the upper limit of normal (N); bilirubin&#xD;
        greater than 3N; AST or ALT greater than 3 N.&#xD;
&#xD;
        Progressive disease of malignant, psychiatric, cardiac, pulmonary, thyroid, renal or&#xD;
        neurological (peripheral or central) origin or severe disorders of hemostasis.&#xD;
&#xD;
        Severe uncontrolled hypertension.&#xD;
&#xD;
        Previous or progressive pathology contraindicating the administration of IL-2.&#xD;
&#xD;
        History of extensive psoriasis, Crohn's disease or auto-immune disease involving severe&#xD;
        complications.&#xD;
&#xD;
        HTLV-1 infection (ELISA positive).&#xD;
&#xD;
        Hepatitis B virus co-infection treated with lamivudine or tenofovir or adefovir.&#xD;
&#xD;
        Since atazanavir use can be associated with higher bilirubin levels (mostly indirect) in&#xD;
        the absence of clinical consequences, subjects on atazanavir with bilirubin up to 4.5 times&#xD;
        N may be allowed to participate if the levels have been stable and after approval by the PI&#xD;
        or the PI designated covering physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Lévy, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Henri Mondor Créteil, FRANCE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irini Sereti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Arnó A, Ruiz L, Juan M, Jou A, Balagué M, Zayat MK, Marfil S, Martínez-Picado J, Martínez MA, Romeu J, Pujol-Borrell R, Lane C, Clotet B. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with &lt;/=250/microL CD4 T cells and undetectable plasma virus load. J Infect Dis. 1999 Jul;180(1):56-60.</citation>
    <PMID>10353861</PMID>
  </reference>
  <reference>
    <citation>Carr A, Emery S, Lloyd A, Hoy J, Garsia R, French M, Stewart G, Fyfe G, Cooper DA. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group. J Infect Dis. 1998 Oct;178(4):992-9.</citation>
    <PMID>9806026</PMID>
  </reference>
  <reference>
    <citation>Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000 Oct 21;356(9239):1423-30. Review.</citation>
    <PMID>11052597</PMID>
  </reference>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>November 3, 2003</study_first_submitted>
  <study_first_submitted_qc>November 3, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2003</study_first_posted>
  <results_first_submitted>September 13, 2010</results_first_submitted>
  <results_first_submitted_qc>September 13, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2010</results_first_posted>
  <last_update_submitted>September 13, 2010</last_update_submitted>
  <last_update_submitted_qc>September 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Irini Sereti, M.D./National Institute of Allergy and Infectious Diseases</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>Interleukin 2</keyword>
  <keyword>Treatment Interruption</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From November 2003 to July 2006, 148 patients were randomized (81 in the IL-2 arm and 67 in the control arm in one centre of the NIH (USA) and 21 centres of the ANRS network (France).</recruitment_details>
      <pre_assignment_details>31 patients were not included because : CD4 below 500 (n=8), patient decision (n=6), HIV RNA &lt; 50 copies/ml (n=5), neutropenia or high bilirubin(n=3), CD4 nadir below 200 (n=2),other diseases (n=2), AIDS (n=1), other reason (n=4)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Interleukin-2 Group</title>
          <description>HAART and tree cycles of IL-2</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>HAART alone (without Interleukin-2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81">3 patients did not received Interleukin-2</participants>
                <participants group_id="P2" count="67">1 patients stopped HAART at week 0</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81">1 withdrawal&#xD;
1 death 81 patients analysed</participants>
                <participants group_id="P2" count="67">1 withdrawal&#xD;
1 lost of follow-up&#xD;
1 death 67 patients analysed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Interleukin-2 Group</title>
          <description>HAART and tree cycles of IL-2</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>HAART alone (without Interleukin-2)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="148"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="8"/>
                    <measurement group_id="B2" value="44" spread="9"/>
                    <measurement group_id="B3" value="43" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 at inclusion</title>
          <units>cells per mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="770" lower_limit="646" upper_limit="876"/>
                    <measurement group_id="B2" value="735" lower_limit="625" upper_limit="834"/>
                    <measurement group_id="B3" value="747" lower_limit="637" upper_limit="851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 nadir</title>
          <units>cells per mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="326" lower_limit="264" upper_limit="438"/>
                    <measurement group_id="B2" value="328" lower_limit="259" upper_limit="355"/>
                    <measurement group_id="B3" value="326" lower_limit="263" upper_limit="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Without Failure of Strategy From Week 0 to Week 72</title>
        <description>A failure of strategy is defined on the first occurrence of one of the following events:&#xD;
CD4 T-lymphocyte count becomes &lt; 350 cells/mm3 between Wk0 and Wk72 (count confirmed by a 2nd measurement after 2-4 weeks&#xD;
Planned interruption of therapy at Wk24 cannot be done for any reason;&#xD;
Anti-retroviral treatment is restarted between Wk24 and Wk72 for any reason&#xD;
Subject experiences clinical progression of HIV infection to a stage C AIDS diagnosis (appendix I)&#xD;
Subject expires between Wk0 and Wk72 (whatever the cause of death)&#xD;
Subject is lost to follow up</description>
        <time_frame>week 72</time_frame>
        <population>Intent to treat analysis, missing = failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Interleukin-2 Group</title>
            <description>HAART and tree cycles of IL-2</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>HAART alone (without Interleukin-2)</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Without Failure of Strategy From Week 0 to Week 72</title>
          <description>A failure of strategy is defined on the first occurrence of one of the following events:&#xD;
CD4 T-lymphocyte count becomes &lt; 350 cells/mm3 between Wk0 and Wk72 (count confirmed by a 2nd measurement after 2-4 weeks&#xD;
Planned interruption of therapy at Wk24 cannot be done for any reason;&#xD;
Anti-retroviral treatment is restarted between Wk24 and Wk72 for any reason&#xD;
Subject experiences clinical progression of HIV infection to a stage C AIDS diagnosis (appendix I)&#xD;
Subject expires between Wk0 and Wk72 (whatever the cause of death)&#xD;
Subject is lost to follow up</description>
          <population>Intent to treat analysis, missing = failure.</population>
          <units>Pourcentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="63" upper_limit="83"/>
                    <measurement group_id="O2" value="55" lower_limit="43" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in CD4 Counts at Week 72</title>
        <time_frame>week 72</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Interleukin-2 Group</title>
            <description>HAART and tree cycles of IL-2</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>HAART alone (without Interleukin-2)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CD4 Counts at Week 72</title>
          <units>cells per mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541" lower_limit="398" upper_limit="702"/>
                    <measurement group_id="O2" value="453" lower_limit="379" upper_limit="580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <p_value_desc>Biphasic decline of CD4 after week 24 : first slope before W32 and weaker decline until W168.Slopes significantly different (all p values ≤0.0001) between the 2 groups, more pronounced in the IL-2 groups</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AIDS Events</title>
        <description>AIDS defined events according to CDC classification</description>
        <time_frame>Overall study</time_frame>
        <population>IL-2 arm : Oesophageal candidasis at W196&#xD;
Control arm :Ocular B-cell lymphoma at W43,Oesophageal candidasis at W82, B-cell lymphoma at W104</population>
        <group_list>
          <group group_id="O1">
            <title>Interleukin-2 Group</title>
            <description>HAART and tree cycles of IL-2</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>HAART alone (without Interleukin-2)</description>
          </group>
        </group_list>
        <measure>
          <title>AIDS Events</title>
          <description>AIDS defined events according to CDC classification</description>
          <population>IL-2 arm : Oesophageal candidasis at W196&#xD;
Control arm :Ocular B-cell lymphoma at W43,Oesophageal candidasis at W82, B-cell lymphoma at W104</population>
          <units>event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Interleukin-2 Group</title>
          <description>HAART and tree cycles of IL-2</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>HAART alone (without Interleukin-2)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review results communications prior to public release and can embargo communications regarding trial results with no delay specified</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pr G. Chene</name_or_title>
      <organization>INSERM U897 Bordeaux FRANCE</organization>
      <phone>557571392 ext +33</phone>
      <email>genevieve.chene@isped.u-bordeaux2.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

